Polatuzumab Vedotin-piiq
Zanubrutinib
Ibrutinib Plus Bendamustine and Rituximab
Lymphoma Research Foundation
COVID-19 and Aggressive Lymphoma: Frequently Asked Questions Answered by ASH
Leukemia & Lymphoma Society
JNCCN: How to Manage Cancer Care During COVID-19 Pandemic